Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Seltzer

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
American Heart Journal|February 3, 2015
Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research ConsortiumJonathan H Seltzer, J Rick Turner, Mary Jane Geiger, et al.
American Heart Journal|May 15, 2018
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?Noel Chan, Philip T Sager, Jack Lawrence, et al.
Journal of the American College of Cardiology|March 15, 2018
Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 DiabetesStephen J Greene, Muthiah Vaduganathan, Muhammad Shahzeb Khan, et al.
American Heart Journal|May 11, 2020
Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think TankJonathan H Seltzer, Ann Farrell, Neil Goldenberg, et al.
Circulation Research|October 26, 2018
A Path Forward for Regenerative MedicineAlexander C Fanaroff, Valarie Morrow, Mitchell W Krucoff, et al.
Therapeutic Innovation & Regulatory Science|February 20, 2020
Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future DirectionsGreg Ball, Raffael Kurek, Barbara A Hendrickson, et al.
JACC. Cardiovascular Interventions|May 11, 2019
Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance DocumentErnest Spitzer, Eugene McFadden, Pascal Vranckx, et al.
American Heart Journal|June 2, 2015
Novel oral anticoagulants and reversal agents: Considerations for clinical developmentTroy C Sarich, Jonathan H Seltzer, Scott D Berkowitz, et al.
Journal of the American College of Cardiology|April 16, 2021
Gaining Efficiency in Clinical Trials With Cardiac Biomarkers: JACC Review Topic of the WeekJames L Januzzi, John M Canty, Saumya Das, et al.
American Heart Journal|October 4, 2020
Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shockMarc D Samsky, Mitchell W Krucoff, David A Morrow, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
American Heart Journal|February 3, 2015
Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research ConsortiumJonathan H Seltzer, J Rick Turner, Mary Jane Geiger, et al.
American Heart Journal|May 15, 2018
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?Noel Chan, Philip T Sager, Jack Lawrence, et al.
Journal of the American College of Cardiology|March 15, 2018
Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 DiabetesStephen J Greene, Muthiah Vaduganathan, Muhammad Shahzeb Khan, et al.
American Heart Journal|May 11, 2020
Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think TankJonathan H Seltzer, Ann Farrell, Neil Goldenberg, et al.
Circulation Research|October 26, 2018
A Path Forward for Regenerative MedicineAlexander C Fanaroff, Valarie Morrow, Mitchell W Krucoff, et al.
Therapeutic Innovation & Regulatory Science|February 20, 2020
Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future DirectionsGreg Ball, Raffael Kurek, Barbara A Hendrickson, et al.
JACC. Cardiovascular Interventions|May 11, 2019
Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance DocumentErnest Spitzer, Eugene McFadden, Pascal Vranckx, et al.
American Heart Journal|June 2, 2015
Novel oral anticoagulants and reversal agents: Considerations for clinical developmentTroy C Sarich, Jonathan H Seltzer, Scott D Berkowitz, et al.
Journal of the American College of Cardiology|April 16, 2021
Gaining Efficiency in Clinical Trials With Cardiac Biomarkers: JACC Review Topic of the WeekJames L Januzzi, John M Canty, Saumya Das, et al.
American Heart Journal|October 4, 2020
Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shockMarc D Samsky, Mitchell W Krucoff, David A Morrow, et al.
Pageof 8